hackint0sh/New-Dataset huggingface dataset:
In line with this plan, an exercise reconditioning program has been set up at our facility. This three-month stay includes children with a variety of pathologies, but with a common feature of physical deconditioning. conditions: Children With Cerebral Palsy conditions: Children With Cancer studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 50 type: ESTIMATED measure: Diagnoform test score measure: KidScreen52 quality-of-life scale score. measure: Impedance measurement measure: Exercise test on ergometer measure: Anamnesis measure: 6-minute walk test measure: Energy expenditure index measure: Gluteal bridge measure: Shirado test measure: Sorensen test measure: Timed Up and Down Stairs (TUDS) test measure: Floor survey test measure: Mini Bestest : Each of the 14 tests is graded from 0 to 2. "0" represents the lowest functional level and "2" the highest functional level. Maximal score : 28. measure: The Canadian Occupational Performance Measure measure: A motivational questionnaire sex: ALL minimumAge: 8 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: Institut Régional de Médecine Physique et de Réadaptation status: RECRUITING city: Nancy zip: 54000 country: France name: Jonathan Pierret, PhD role: CONTACT phone: +33 3 82 52 6761 email: jonathan.pierret@ugecam.assurance-maladie.fr lat: 48.68439 lon: 6.18496 hasResults: False
nctId: NCT06320470 id: HUM00231159a id: VMR2022-03 type: OTHER_GRANT domain: Michigan, State of, Licensing and Regulatory Affairs, Department of 573000 briefTitle: MIVetsCan: Can-Coach Trial (Phase 1) overallStatus: COMPLETED date: 2023-08-07 date: 2023-12-11 date: 2023-12-11 date: 2024-03-20 date: 2024-03-20 name: University of Michigan class: OTHER name: Michigan, State of, Licensing and Regulatory Affairs briefSummary: The goal of the MIVetsCan Can-Coach Trial is to pilot and modify a trial of four coaching sessions to help Veterans with chronic pain use their own cannabis products more effectively to manage pain and related symptoms. conditions: Chronic Pain studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: PREVENTION masking: NONE count: 22 type: ACTUAL name: Educational Session measure: Patient Global Impression of Change (PGIC) score measure: Average satisfaction level of the cannabis coaching overall assessed from a single survey question on satisfaction. measure: Average helpfulness level of the cannabis coaching assessed from a single survey question on cannabis coaching. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The University of Michigan city: Ann Arbor state: Michigan zip: 48109 country: United States lat: 42.27756 lon: -83.74088 hasResults: False
nctId: NCT06320457 id: 2024-00095 briefTitle: A Brief Case Management Intervention for People Involuntarily Admitted to a Psychiatric Hospital acronym: CARP overallStatus: NOT_YET_RECRUITING date: 2024-03-21 date: 2024-10-21 date: 2024-10-31 date: 2024-03-20 date: 2024-03-27 name: University of Lausanne Hospitals class: OTHER briefSummary: The goal of this clinical trial is to assess whether a brief case management intervention aimed at promoting personal recovery and reducing the negative effects of coercion among people involuntarily admitted to a psychiatric hospital would be well accepted by them, practically feasible and useful. The main questions it aims to answer are:
* a final in-depth semi-structured interview (optional). conditions: Psychiatric Disorder conditions: Involuntary Psychiatric Hospitalization studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: OTHER masking: NONE count: 36 type: ESTIMATED name: Brief case management intervention measure: Eligibility rate measure: Participation rate measure: Drop-out rate measure: Intervention dosage measure: Missing data rates measure: Number of unexpected adverse events measure: Participants' acceptance and degree of satisfaction measure: Implementation barriers and facilitating factors measure: Recovery Assessment Scale (RAS) measure: Empowerment Scale measure: Rosenberg Self-Esteem Scale (RSS) measure: The Paradox of Self-Stigma scale (PaSS-24) measure: Beck Hopelessness Scale (BHS) measure: WHOQOL-BREF measure: International Trauma Questionnaire (ITQ) measure: Coercion Ladder (CL) measure: Index of fairness and Index of effectiveness measure: Satisfaction with hospital care measure: Brief INSPIRE scale sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Lausanne University Hospital city: Lausanne state: Canton Of Vaud zip: 1003 country: Switzerland name: Stéphane Morandi role: CONTACT phone: +41 21 3140050 email: stephane.morandi@chuv.ch name: Stéphane Morandi role: PRINCIPAL_INVESTIGATOR lat: 46.516 lon: 6.63282 hasResults: False
nctId: NCT06320444 id: CRFSJ0297 briefTitle: Non-invasive Spinal, Cortical, and Sensorimotor Biomarkers in Motor Neurone Disease overallStatus: RECRUITING date: 2023-06-15 date: 2024-12-15 date: 2025-07-15 date: 2024-03-20 date: 2024-03-20 name: University of Dublin, Trinity College class: OTHER name: Motor Neurone Disease Association, UK name: Irish Research Council, IE name: Health Research Board, IE name: Research Motor Neurone, IE name: Thierry Latran Foundation, FR name: ALS Association, USA briefSummary: Substantial variability exists in the onset, and rate of degeneration across individuals with Motor Neurone Disease (MND) or Amyotrophic Lateral Sclerosis (ALS). This variability requires biomarkers that accurately classify and reliably track clinical subtypes as the disease progresses. Degeneration occurs in the brain and spinal cord, however, non-invasive diagnosis of spinal cord function remains highly challenging due to its unique alignment in spine. Disruption of complex spinal and cortical circuits that transmit and process neural signals for position sense and movement has not been adequately captured in the neurophysiological profiling of ALS patients. The overarching aim of this study is to reveal and quantify the extent of change in the sensorimotor integration and its potential contribution to network disruption in ALS. conditions: Motor Neuron Disease, Amyotrophic Lateral Sclerosis conditions: Motor Neuron Disease Progressive Spinal Muscle Atrophy conditions: Primary Lateral Sclerosis conditions: Multiple Sclerosis conditions: Postpoliomyelitis Syndrome studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 240 type: ESTIMATED name: 232 Electrode Electrophysiology (EEG-ECG-EMG-EXG) measure: Biomarker of sensorimotor integration measure: Determination of the feasibility of sensorimotor signatures as reliable biomarkers of ALS measure: Non-invasive recording of the SC functional neuro-electric activity sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Academic Unit of Neurology, Trinity College Dublin, The University of Dublin status: RECRUITING city: Dublin state: Leinster zip: Dublin 2 country: Ireland name: Orla Hardiman,, BSc MB BCh BAO MD FRCPI FAAN role: CONTACT phone: +353 1 896 4497 email: hardimao@tcd.ie name: Prabhav Mehra, BE MSc role: CONTACT phone: +3530894781347‬ email: mehrap@tcd.ie lat: 53.33306 lon: -6.24889 hasResults: False
nctId: NCT06320431 id: ACT-WHEN-001 briefTitle: ACT-GLOBAL THROMBOLYSIS (ACT-WHEN-001) Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632 acronym: ACT-WHEN overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2030-09-30 date: 2030-12-31 date: 2024-03-20 date: 2024-04-25 name: University of Calgary class: OTHER name: The George Institute for Global Health, Australia briefSummary: This domain has a prospective, randomized, controlled, open-label, parallel group with blinded endpoint assessment (PROBE) design. Up to 4,000 patients with presumed acute ischemic stroke (AIS) will be followed for 90 days (or until death, if prior to 90 days). The end of the trial is defined as the date that all participants have completed their Day 90 assessment.
This domain aim is to efficiently, reliably, and simultaneously, determine the comparative effectiveness of intravenous thrombolysis (IVT) using standard-dose intravenous tenecteplase (0.25 mg/kg body weight), vs. low-dose intravenous tenecteplase (0.18 mg/kg body weight) in all patients who present to hospital with acute ischemic stroke and are considered for intravenous thrombolysis. In addition, this domain also seeks to study standard-dose intravenous tenecteplase (0.25 mg/kg body weight), vs. low-dose intravenous tenecteplase (0.18 mg/kg body weight) vs. no TNK upfront with rescue IA TNK if necessary (in those eligible for emergency EVT) and no TNK upfront in those who have taken DOACs during the preceding 24 hours. This domain therefore seeks to generate more robust randomized evidence to guide clinicians in their decisions over the balance of risks and treatment with intravenous thrombolysis with tenecteplase wherever such evidence is currently insufficient.
4. To what extent is the treatment effect of standard- vs. low-dose tenecteplase modified by key patient characteristics, such as diabetes, prior antiplatelet therapy, renal failure, or frailty, old age or having a heavy burden of cerebral small vessel disease on brain imaging. conditions: Acute Ischemic Stroke AIS conditions: Stroke Acute conditions: Stroke, Acute, Stroke Ischemic studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomization will be stratified by: (1) planned emergency endovascular thrombectomy (EVT) and (2) known use or history to suggest use of a standard-dose direct oral anticoagulant (DOAC) within the last 24 hours. Randomization will be centralized, secure and concealed, using a web-based server and permuted blocks of varying sizes will be used.
Patients in strata 1, 2 and 3 will be randomized to standard-dose IV tenecteplase (0.25 mg/kg body weight) vs. Low-dose tenecteplase (0.18 mg/kg body weight) or no IV thrombolysis (1:1:1 randomization). Patients in strata 4 will be randomized to standard-dose intravenous (IV) tenecteplase (0.25 mg/kg body weight) vs. Low-dose IV tenecteplase (0.18 mg/kg body weight) only (1:1 randomization).
Emergency EVT is defined as anticipated arterial puncture time in the enrolling hospital ≤ 60 minutes from randomization. primaryPurpose: TREATMENT masking: SINGLE maskingDescription: The trial will have allocation concealment and blinded endpoint assessment, but open-label treatment. Given the time sensitive nature of acute stroke treatment, blinding the enrolling personnel to treatment assignment is not practical. Clinical site staff, including the Principal Investigator (PI), sub-investigators, clinic site staff, and the Sponsor will not be blinded to treatment allocated or received. In the event of an emergency the PI will be already unblinded.
The trial will have blinded endpoint assessment on Day 90, with central blinded assessors contacting the participants. whoMasked: OUTCOMES_ASSESSOR count: 4000 type: ESTIMATED name: Tenecteplase measure: A reduction of functional dependence analyzed across the whole distribution of outcomes assessed on the modified Rankin Scale (mRS), measure: 90-day mortality measure: Proportion of participants with a Modified Rankin Scale (mRS) of 0-1 at Day 90. measure: Proportion of participants with a Modified Rankin Scale (mRS) of 0-2 at Day 90. measure: Health-related quality of life, as measured by the EQ-5D-5L at Day 90. measure: The frequencies of Serious Adverse Events (SAEs) from enrollment up to Day 4 measure: Symptomatic intracranial hemorrhage measure: Large parenchymal hemorrhage (PH-2) measure: Ordinal shift of 7 levels of mRS at 90 days measure: Proportion of participants achieving first pass (eTICI 2c or higher) reperfusion (when treated with EVT). measure: Proportion of participants achieving successful recanalization (revised arterial occlusive lesion [rAOL] score of 2b-3) at first angiographic acquisition (when treated with EVT). measure: Ambulatory status at discharge measure: Place of residence at 90 days measure: Imaging assessment (e.g., infarct size and edema volume) measure: Summative total length of hospital stay in the first 90-days after stroke onset sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The George Institute for Global Health city: Sydney state: Barangaroo zip: NSW 2000 country: Australia name: Xiaoying Chen, PHD role: CONTACT email: xchen@georgeinstitute.org.au name: Craig Anderson, MD role: PRINCIPAL_INVESTIGATOR lat: -33.86785 lon: 151.20732 facility: University of Calgary city: Calgary state: Alberta zip: T2N 1N4 country: Canada name: Carol C Kenney, RN role: CONTACT phone: 4039444286 email: ckenney@ucalgary.ca name: Michael D Hill, MD role: CONTACT email: michael.hill@ucalgary.ca name: Michael D Hill, MD role: PRINCIPAL_INVESTIGATOR lat: 51.05011 lon: -114.08529 hasResults: False
nctId: NCT06320418 id: RHDIRB2020110301REC#196 briefTitle: The Epigenetic Regulatory Role of P-element Induced Wimpy Testis (Piwi) Interacting RNA-823 (piR-823) in Ovarian Cancer Progression overallStatus: ACTIVE_NOT_RECRUITING date: 2022-06-15 date: 2023-12-10 date: 2024-06 date: 2024-03-20 date: 2024-03-20 name: Ain Shams University class: OTHER briefSummary: Ovarian cancer (OC) has one of the highest mortality rates for female malignant tumors, attributed to advanced cancer stages upon diagnosis as well as a high recurrence rate. Piwi-interacting RNA-823 (piR-823) is a single-stranded non-protein coding RNA (ncRNA) star molecule in epigenetics research. Extensive cellular regulatory functions and aberrant expression of piR-823 have been implicated in carcinogenesis. Therefore, the findings of piwi-ncRNA dysregulated-expression in OC Egyptian female patients' cohort could be employed as a potential novel mechanism for OC precision, a step toward ncRNA-precision conditions: Ovarian Cancer studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: RETROSPECTIVE count: 56 type: ACTUAL measure: Association of piR-823 expression with ovarian cancer progression sex: FEMALE stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Faculty of Pharmacy, Ain Shams University, Advanced Biochemistry Research Lab city: Cairo zip: 11566 country: Egypt lat: 30.06263 lon: 31.24967 hasResults: False
nctId: NCT06320405 id: STUDY00025940 id: NCI-2024-01397 type: REGISTRY domain: CTRP (Clinical Trial Reporting Program) id: STUDY00025940 type: OTHER domain: OHSU Knight Cancer Institute briefTitle: Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2027-04-01 date: 2029-04-01 date: 2024-03-20 date: 2024-03-20 name: OHSU Knight Cancer Institute class: OTHER name: Oregon Health and Science University name: Incyte Corporation briefSummary: This phase I/II trial tests the safety, side effects, and effectiveness of axatilimab in combination with retifanlimab and paclitaxel for the treatment of patients with a solid tumor that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). Axatilimab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Immunotherapy with monoclonal antibodies, such as retifanlimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Giving axatilimab in combination with retifanlimab and paclitaxel may be safe, tolerable and/or effective in treating patients with advanced or metastatic solid tumors. conditions: Advanced Malignant Solid Neoplasm conditions: Metastatic Malignant Solid Neoplasm conditions: Recurrent Malignant Solid Neoplasm conditions: Refractory Malignant Solid Neoplasm studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 38 type: ESTIMATED name: Axatilimab name: Biopsy name: Biospecimen Collection name: Computed Tomography name: Magnetic Resonance Imaging name: Paclitaxel name: Positron Emission Tomography name: Retifanlimab measure: Incidence of dose limiting toxicities (phase Ib) measure: Recommended phase 2 dose of the study drug combination (phase Ib) measure: Clinical benefit rate (phase Ib/II) measure: Incidence of ≥ grade 3 toxicities possibly or definitely related to study drugs measure: Changes in immune cell composition and functionality measure: Change in immune cell population sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: OHSU Knight Cancer Institute city: Portland state: Oregon zip: 97239 country: United States name: Shivaani Kummar role: CONTACT phone: 503-494-6594 email: kummar@ohsu.edu name: Shivaani Kummar role: PRINCIPAL_INVESTIGATOR lat: 45.52345 lon: -122.67621 hasResults: False
nctId: NCT06320392 id: RHDIRB2020110301 REC#48 briefTitle: Implication of CCR4-NOT Complex Subunit 7 Expression in Natural Killer Cell Resistance in Metastatic Breast Cancer acronym: CCR4-NOT overallStatus: ACTIVE_NOT_RECRUITING date: 2021-07-01 date: 2023-05-01 date: 2024-06-01 date: 2024-03-20 date: 2024-03-20 name: Ain Shams University class: OTHER briefSummary: Being a mechanistic study, this work aims to figure out "the role of the cytoplasmic mRNA deadenylase CNOT7 expressed protein on NK cell resistance in metastatic BC". In other words, to explore, whether, "CNOT7 contributes to metastasis in Egyptian female metastatic BC patient's cohort, through NK cell resistance, or not." conditions: Metastatic Breast Cancer studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: RETROSPECTIVE count: 90 type: ACTUAL measure: Cytoplasmic mRNA deadenylase CNOT7 protein expression level in metastatic/advanced localized and non-metastatic BC sera using ELISA. measure: CNOT7 tissue expression level in BC tissue samples categorized as metastatic vs non-metastatic tumor alongside with adjacent non-tumor tissue margin using immunohistochemistry. measure: LAIR-1 protein expression level in BC patients peripheral blood samples using ELISA. sex: FEMALE stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Faculty of Pharmacy, Ain Shams University, Advanced Biochemistry Research Lab city: Cairo zip: 11566 country: Egypt lat: 30.06263 lon: 31.24967 hasResults: False
nctId: NCT06320366 id: 23-1044 id: K24DA058882 type: NIH link: https://reporter.nih.gov/quickSearch/K24DA058882 briefTitle: Testing an Accelerated TMS Protocol for Methamphetamine Use Disorder overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2028-05-31 date: 2028-05-31 date: 2024-03-20 date: 2024-03-21 name: University of Colorado, Denver class: OTHER name: National Institute on Drug Abuse (NIDA) briefSummary: The investigators will evaluate the effects of an accelerated Transcranial Magnetic Stimulation (TMS) protocol of the left dorsolateral prefrontal cortex (DLPFC) for moderate to severe methamphetamine use disorder. This is a randomized parallel group design to assess feasibility and safety, evaluate efficacy (use, craving) and identify magnetic resonance imaging (resting state and cue craving) associated with group/outcomes. conditions: Methamphetamine Use Disorder studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Sham vs. real Transcranial Magnetic Stimulation (TMS) primaryPurpose: TREATMENT masking: TRIPLE maskingDescription: Participant and all study personnel are blinded. whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 20 type: ESTIMATED name: Sham TMS name: Active TMS measure: Tolerability measure: Study emergent adverse events measure: Weeks of continuous abstinence measure: Days of methamphetamine use measure: Methamphetamine craving measure: Methamphetamine craving on visual analog scale measure: MRI cue craving measure: MRI resting state sex: ALL minimumAge: 21 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Colorado Anschutz Medical Campus city: Aurora state: Colorado zip: 80045 country: United States name: Joseph T Sakai, MD role: CONTACT phone: 303-724-7402 email: joseph.sakai@cuanschutz.edu name: Kristen M Raymond, BA role: CONTACT phone: 303-724-3196 email: kristen.raymond@cuanschutz.edu name: Joseph T Sakai, MD role: PRINCIPAL_INVESTIGATOR lat: 39.72943 lon: -104.83192 hasResults: False
nctId: NCT06320353 id: CL01860211 briefTitle: Study сomparing the Efficacy and Safety of RPH-075 and Keytruda® in Patients With Unresectable or Metastatic Skin Melanoma overallStatus: ACTIVE_NOT_RECRUITING date: 2023-09-27 date: 2024-06 date: 2026-01 date: 2024-03-20 date: 2024-03-20 name: R-Pharm class: INDUSTRY name: Data Management 365 name: Exacte Labs LLC name: Federal State Budgetary Institution of the Central Research Institute of Epidemiology of Rospotrebnadzor briefSummary: The goal of this double-blind, randomized study is to establish the equivalence of the efficacy, safety and immunogenicity of the drugs RPH-075 (international nonproprietary name (INN) is pembrolizumab) and Keytruda® (INN is pembrolizumab) when used in patients with unresectable or metastatic skin melanoma first or second line therapy in a monotherapy regimen.
nctId: NCT06320340 id: 07032024 briefTitle: Effectiveness of NMES on Neck Pain overallStatus: COMPLETED date: 2021-03-15 date: 2021-05-15 date: 2021-09-15 date: 2024-03-20 date: 2024-03-20 name: Istanbul University - Cerrahpasa (IUC) class: OTHER briefSummary: The aim of this randomized-controlled study was to determine the effectiveness of neuromuscular electrical stimulation (NMES) applied simultaneously to exercise on pain, static endurance of cervical deep flexor muscles, fear of movement and disability in chronic neck pain. The participants were randomly assigned to one group which in only five clinical pilates exercises were performed (Group I) or the other group which NMES was applied on lower trapezius and serratus anterior muscles while the same exercises were performing (Group II). conditions: Chronic Neck Pain studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 36 type: ACTUAL name: Exercise name: Electrotherapy measure: Neck disability measure: Neck disability measure: Pain intensity measure: Pain intensity measure: Range of Motion measure: Range of Motion measure: Static endurance of cervical deep flexor muscles measure: Static endurance of cervical deep flexor muscles measure: Fear of the movement measure: Fear of the movement sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: İstanbul Aydın University city: İstanbul country: Turkey lat: 41.01384 lon: 28.94966 hasResults: False
nctId: NCT06320327 id: 80177 briefTitle: Topical CBD's Effects on Soreness and Performance overallStatus: COMPLETED date: 2022-08-23 date: 2023-04-27 date: 2023-04-30 date: 2024-03-20 date: 2024-03-20 name: Joseph Pastina class: OTHER briefSummary: Exercise-induced muscle damage (EIMD) results from unaccustomed exercise and can lead to delayed onset muscle soreness (DOMS). Impairments associated with EIMD and DOMS can result in moderate-to-severe discomfort and hindered performance. Recently, a compound derived from the cannabis plant, cannabidiol (CBD), has been used as a recovery tool for EIMD and DOMS. Despite the rising popularity of CBD products, their effectiveness in mitigating EIMD and DOMS is unknown. Specifically, to the investigators' knowledge, no clinical trials have been completed to assess the effects of topical CBD cream application on soreness, recovery and performance.